Summary Australian and New Zealand clinical practice guideline for the treatment of schizophrenia 2003

REFERENCES

• Jablensky A, McGrath J, Herrman H, et al. People Living with Psychotic Illness: An Australian Study 1997–98 An Overview. Overview of the Method and Results of Low Prevalence (Psychotic) Disorders as part of the National Survey of Mental Health and Wellbeing. Low Prevalence Disorders Study Group, Commonwealth Department of Health and Age Care, Canberra 1999
   Google Scholar
• Boyce P, Ellis P, Penrose-Wall J. The Australian and New Zealand Clinical Practice Guidelines for Specialist Adult Mental Health Care: An introduction. Australasian Psychiatry 2003; 1: 21–25
   Google Scholar
• Harrison G, Hopper K, Craig T, et al. Recovery from psychotic illness: A 15- and 25- year international follow-up study. British Journal of Psychiatry 2001; 178: 506–517
   PubMed Web of Science ®Google Scholar
• SANE Australia. Schizophrenia: Costs. An Analysis of the Burden of Schizophrenia and Related Suicide in Australia. 2002, Access Economics Report
   Google Scholar
• Coghlan R, Lawrence D, Holman C, Jablensky A. Duty to Care: Physical Illness in People with Mental Illness. University of Western Australia, Perth 2001
   Google Scholar
• Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. British Journal of Psychiatry 2000; 177: 212–217
   PubMed Web of Science ®Google Scholar
• Carr V, Neil A, Halpin S, Holmes S. Costs of psychosis in urban Australia. National Survey of Mental Health and Wellbeing Bulletin 2. Low Prevalence Disorders Study Group, Commonwealth Department of Health and Age Care, Canberra 2002
   Google Scholar
• McGorry P. Translating advances in schizophrenia treatment: a glass ceiling. Medical Journal of Australia, in press
   Web of Science ®Google Scholar
• Pantelis C, Velakoulis D, McGorry P D, et al. Neuroanatomical abnormalities in people who develop psychosis. Lancet 2003; 361: 281–288
   PubMed Web of Science ®Google Scholar
• McGorry P D, Yung A R, Phillips L J, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry 2002; 59: 921–928
   PubMed Web of Science ®Google Scholar
• Yung A R, Phillips L J, Yuen H P, et al. Psychosis prediction: 12-month follow up of a high risk (‘prodromal’) group. Schizophrenia Research 2003; 60: 21–32
   PubMed Web of Science ®Google Scholar
• Woods S, Zipursky R, Perkins D, Addington J, Marquez E, Breier A, McGlashan T H. Olanzapine vs. placebo for prodromal symptoms. Acta Psychiatrica Scandinavica 2002; 106: S413–43
   Google Scholar
• Cornblatt B, Lencz T, Correll C, Author A, Smith C. Treating the prodrome: Naturalistic findings from the RPA Program. Acta Psychiatrica Scandinavica 2002; 106(S413)44
   Google Scholar
• Bechdolf A, Wagner M, Hambrecht M. Psychological intervention in the prepsychotic phase: preliminary results of a multicentre trial. Acta Psychiatrica Scandinavica 2002; 106(S413)41
   Google Scholar
• McGlashan T. Duration of untreated psychosis in first-episode schizophrenia: Marker or determinant of course?. Biological Psychiatry 1999; 46: 899–907
   PubMed Web of Science ®Google Scholar
• The Recognition and Management of Early Psychosis: A Preventive Approach, P D McGorry, H Jackson. Cambridge University Press, UK 1999
   Google Scholar
• Early Intervention in Psychosis. A Guide to Concepts, Evidence and Intervention, M Birchwood, D Fowler, C Jackson. Wiley, Chichester 2000
   Google Scholar
• The Early Stages of Schizophrenia, R B Zipursky, S C Schulz. American Psychiatric Publishing, Washington DC 2002
   Google Scholar
• Implementing Early Intervention in Psychosis: A Guide to Establishing Early Psychosis Services, J Edwards, P D McGorry. Dunitz, London 2002
   Google Scholar
• National Service Framework for Mental Health: Modern Standards and Service Models. Department of Health, London 2000
   Google Scholar
• Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. Abba Litho Sales, London 2002
   Google Scholar
• Harrigan S M, McGorry P D, Krstev H. Does treatment delay in first-episode psychosis really matter?. Psychological Medicine 2003; 33: 97–110
   PubMed Web of Science ®Google Scholar
• Norman R MG, Malla A K. Duration of untreated psychosis: A critical examination of the concept and its importance. Psychological Medicine 2001; 31: 381–400
   PubMed Web of Science ®Google Scholar
• Malla A K, Norman R MG. Early intervention in schizophrenia and related disorders: Advantages and pitfalls. Current Opinion in Psychiatry 2002; 15: 17–23
   Web of Science ®Google Scholar
• Lieberman J A, Fenton W S. Delayed detection of psychosis: Causes, consequences, and effect on public health. American Journal of Psychiatry 2000; 157: 1727–1730
   PubMed Web of Science ®Google Scholar
• Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: Historical cohort study. British Medical Journal 2002; 325: 1199–1203
   PubMed Web of Science ®Google Scholar
• Linszen D H, Dingemans P M, Lenior M E. Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry 1994; 51: 273–279
   PubMed Web of Science ®Google Scholar
• Larsen T K, McGlashan T H, Johannessen J O, et al. Shortened duration of untreated first episode of psychosis: Changes in patient characteristics at treatment. American Journal of Psychiatry 2001; 158: 1917–1919
   PubMed Web of Science ®Google Scholar
• Johannessen J O, McGlashan T H, Larsen T K, et al. Early detection strategies for untreated first-episode psychosis. Schizophrenia Research 2001; 51: 39–46
   PubMed Web of Science ®Google Scholar
• Fitzgerald P, Kulkarni J. Home-oriented management program for people with early psychosis. British Journal of Psychiatry 1998; 172: 39–44, (Suppl. 33)
   Web of Science ®Google Scholar
• McGorry P D, Chanen A, McCarthy E, Van Riel R, McKenzie D, Singh B S. Post-traumatic stress disorder following recent-onset psychosis: An unrecognised post-psychotic syndrome. Journal of Nervous and Mental Disease 1991; 179: 253–258
   PubMed Web of Science ®Google Scholar
• Shaw K, McFarlane A, Bookless C. The phenomenology of traumatic reactions to psychotic illness. Journal of Nervous and Mental Disease 1997; 185: 434–441
   PubMed Web of Science ®Google Scholar
• Meyer H, Taimimen T, Vuori T, Äijalä Ä, Helenius H. Posttraumatic stress disorder symptoms related to psychosis and acute involuntary hospitalization in schizophrenic and delusional patients. Journal of Nervous and Mental Disease 1999; 187: 343–352
   PubMed Web of Science ®Google Scholar
• Remington G, Kapur S, Zipursky R B. Pharmacotherapy of first-episode schizophrenia. British Journal of Psychiatry 1998; 172: 66–70, (Suppl. 33)
   Web of Science ®Google Scholar
• Emsley R A. Risperidone in the treatment of first-episode psychotic patients: A double-blind multicenter study. Risperidone Working Group. Schizophrenia Bulletin 1999; 25: 721–729
   PubMed Web of Science ®Google Scholar
• Merlo M CG, Hofer H, Gekle W, et al. Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: Treatment efficacy and effects on fine motor functioning. Journal of Clinical Psychiatry 2002; 63: 885–891
   PubMed Web of Science ®Google Scholar
• Kapur S, Remington G. Atypical antipsychotics. Patients value the lower incidence of extrapyramidial side effects. British Medical Journal 2000; 321: 1360–1361
   PubMed Web of Science ®Google Scholar
• Geddes J. Prevention of relapse in schizophrenia. New England Journal of Medicine 2002; 346: 56–57
   PubMed Web of Science ®Google Scholar
• Lewis S, Tarrier N, Haddock G, et al. Randomised, cotrolled trial of cognitive-behaviour therapy in early schizophrenia: Acute phase outcomes. British Journal of Psychiatry 2002; 181: S91–S97
   PubMed Web of Science ®Google Scholar
• Jackson H J, McGorry P D, Edwards J, et al. Cognitively-oriented psychotherapy for early psychosis (COPE). Preliminary results. British Journal of Psychiatry 1998; 172: 93–100, (Suppl. 33)
   Web of Science ®Google Scholar
• Gleeson J, Jackson H J, Stavely H, Burnett P. Family intervention in early psychosis. The Recognition and Management of Early Psychsis. A Preventive Approach, P D McGorry, H J Jackson. Cambridge University Press, UK 1999; 376–406
   Google Scholar
• Zhang M, Wang M, Li J, Phillips M R. Randomised-control trial of family intervention for 78 first-episode male schizophrenic patients: An 18-month study in Suzhou, Jiangsu. British Journal of Psychiatry 1994; 24: 96–102, (Suppl.)
   Web of Science ®Google Scholar
• Edwards J, Maude D, Herrman-Doig T, et al. A service response to prolonged recovery in early psychosis. Psychiatric Services 2002; 53: 1067–1069
   PubMed Web of Science ®Google Scholar
• Meltzer H Y, Alphs L, Green A I, et al. for the InterSePT, Study Group. Clozapine Treatment for Suicidality in Schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry 2003; 60: 82–91
   PubMed Web of Science ®Google Scholar
• Robinson D G, Woerner M G, Alvir J MJ, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 1999; 156: 544–549
   PubMed Web of Science ®Google Scholar
• Birchwood M, MacMillian F. Early intervention in schizophrenia. Australian and New Zealand Journal of Psychiatry 1993; 27: 374–378
   PubMed Web of Science ®Google Scholar
• Lenior M E, Dingemans P MAJ, Linszen D H, de Haan L, Schene A H. Social functioning and the course of early-onset schizophrenia. British Journal of Psychiatry 2001; 179: 53–58
   PubMed Web of Science ®Google Scholar
• Power P, Bell R, Mills R, et al. Suicide prevention in first episode psychosis. The development of a randomised controlled trial of cognitive therapy for acutely suicidal patients with early psychosis. Australian and New Zealand Journal of Psychiatry (Suppl.), in press
   Google Scholar
• Drake R E, McHugo G J, Bebout R R, et al. A randomised controlled trial of supported employment for inner-city patients with severe mental illness. Archives of General Psychiatry 1999; 56: 627–633
   PubMed Web of Science ®Google Scholar
• Lehman A F, Goldberg R, Dixon L B, et al. Improving employment outcomes for persons with severe mental illnesses. Archives of General Psychiatry 2002; 59: 165–172
   PubMed Web of Science ®Google Scholar
• Hogarty G, Kornblith S, Greenwald D, et al. Three year trials of personal therapy among schizophrenic patients living with or independent of family, I. Description of study and effects on relapse rates. American Journal of Psychiatry 1997; 154: 1504–1514
   PubMed Web of Science ®Google Scholar
• Hogarty G, Greenwald D, Ulrich R T, et al. Three year trials of personal therapy among schizophrenic patients living with or independent of family, II. Effects on adjustment of patients. American Journal of Psychiatry 1997; 154: 1515–1524
   Web of Science ®Google Scholar
• Pilling S, Bebbington P, Kuipers E, Garety Geddes J, Orbach G, Morgan C. Psychological treatments in schizophrenia. I. Meta-analysis of family intervention and cognitive behaviour therapy. Psychological Medicine 2002; 32: 763–782
   PubMed Web of Science ®Google Scholar
• Pilling S, Bebbington P, Kuipers E, et al. Psychological treatments in schizophrenia. II. Meta-analysis of randomized controlled trials of social skills training and cognitive remediation. Psychological Medicine 2002; 32: 783–791
   PubMed Web of Science ®Google Scholar
• Schooler N J, Keith S J, Severe J B, et al. Relapse and rehospitalisation during maintenance treatment of schizophrenia. The effects of dose reduction and family treamtment. Archives of General Psychiatry 1997; 54: 453–463
   PubMed Web of Science ®Google Scholar
• Czernansky J G, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine 2002; 346: 16–22
   PubMed Web of Science ®Google Scholar
• Marshall M, Lockwood A. Assertive community treatment for people with severe mental disorders (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Barrowclough C, Haddock G, Tarrier N, et al. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. American Journal of Psychiatry 2001; 158: 1706–1713
   PubMed Web of Science ®Google Scholar
• Harris E C, Barraclough B. Excess mortality of mental disorder. British Journal of Psychiatry 1998; 173: 11–53
   PubMed Web of Science ®Google Scholar
• Wykes T, van der Gaag M. Is it time to develop a new cognitive therapy for psychosis-cognitive remediation therapy (CRT)?. Clinical Psychology Review 2001; 8: 1227–1256
   Web of Science ®Google Scholar
• Cohen P, Cohen J. The clinician's illusion. Archives of General Psychiatry 1984; 41: 1178–1182
   PubMed Web of Science ®Google Scholar
• Garety P A, Fowler D, Kuipers E. Cognitive-behavioral therapy for medication-resistant symptoms. Schizophrenia Bulletin 2000; 26: 73–86
   PubMed Web of Science ®Google Scholar
• Kerr I B, Taylor D. Mental health emergencies. Caution is needed with rapid tranquillisation protocol. British Medical Journal 1997; 315: 885
   PubMed Web of Science ®Google Scholar
• Andrews G, Sanderson K, Corry J, Issakidis C, Lapsley H. The cost effectiveness of current and optimal treatment for schizophrenia: Evidence based medicine is affordable. British Journal of Psychiatry 2003; 21: 1227–1256
   Google Scholar
• Barbato A, D'Avanzo B. Family interventions in schizophrenia and related disorders: A critical review of clinical trials. Acta Psychiatrica Scandinavica 2000; 102: 81–97
   PubMed Web of Science ®Google Scholar
• Barbui C, Saraceno B. Low-dose neuroleptic therapy and extrapyramidal side effects in schizophrenia: An effect size analysis. European Psychiatry 1996; 11: 412–415
   PubMed Web of Science ®Google Scholar
• Bech P, Peuskens J C, Marder S R, et al. Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics. European Psychiatry 1998; 13: 310–314
   PubMed Web of Science ®Google Scholar
• Bollini P, Pampallona S, Orza M J, Adams M E, Chalmers T C. Antipsychotic drugs: Is more worse? A meta-analysis of the published randomized control trials. Psychological Medicine 1994; 24: 307–316
   PubMed Web of Science ®Google Scholar
• Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. American Journal of Psychiatry 2001; 158: 518–526
   PubMed Web of Science ®Google Scholar
• Chilvers R, Macdonald G M, Hayes A A. Supported housing for people with severe mental disorders (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Cormac I, Jones C, Campbell C, Silveira da Mota Neto J. Cognitive behaviour therapy for schizophrenia (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Crowther R, Marshall M, Bond G, Huxley P. Vocational rehabilitation for people with severe mental illness (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Cuijpers P. The effects of family interventions on relatives' burden: A meta-analysis. Journal of Mental Health 1999; 8: 275–285
   Google Scholar
• Cure S, Carpenter S. Droperidol for acute psychosis (Cochrane Review). The CochraneLibrary. Issue 1. Update Software, Oxford 2003
   Google Scholar
• de Oliveira I R, Miranda-Scippa A M, de Sena E P, et al. Risperidone versus haloperidol in the treatment of schizophrenia: A meta-analysis comparing their efficacy and safety. Journal of Clinical Pharmacy and Therapeutics 1996; 21: 349–358
   PubMed Web of Science ®Google Scholar
• Drake R E, Mercer-McFadden C, Mueser K T, McHugo G J, Bond G R. Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophrenia Bulletin 1998; 24: 589–608
   PubMed Web of Science ®Google Scholar
• Duggan L, Fenton M, Dardennes R M, El-Dosoky A, Indran S. Olanzapine for schizophrenia (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Fenton M, Coutinho E SF, Campbell C. Zuclopenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. British Medical Journal 2000; 321: 1371–1376
   PubMed Web of Science ®Google Scholar
• Gilbody S M, Bagnall A M, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Gould R A, Mueser K T, Bolton E, Mays V, Goff D. Cognitive therapy for psychosis in schizophrenia: An effect size analysis. Schizophrenia Research 2001; 48: 335–342
   PubMed Web of Science ®Google Scholar
• Hayes R L, McGrath J J. Cognitive rehabilitation for people with schizophrenia and related conditions (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Huxley N A, Rendall M, Sederer L. Psychosocial treatments in schizophrenia: A review of the past 20 years. Journal of Nervous and Mental Disease 2000; 188: 187–201
   PubMed Web of Science ®Google Scholar
• Joy C B, Mumby-Croft R, Joy L A. Polyunsaturated fatty acid (fish or evening primrose oil) for schizophrenia (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Joy C B, Adams C E, Rice K. Crisis intervention for people with severe mental illnesses (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Kennedy E, Song F, Hunter R, Clarke A, Gilbody S. Risperidone versus typical anti-psychotic medication for schizophrenia (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Ley A, Jeffery D P, McLaren S, Siegfried N. Psychosocial treatment programmes for people with both severe mental illness and substance misuse (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: A meta-analysis of randomized controlled trials. Schizophrenia Research 1999; 35: 51–68
   PubMed Web of Science ®Google Scholar
• Malmberg L, Fenton M. Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Marshall M, Lockwood A. Assertive community treatment for people with severe mental disorders (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Marshall M, Gray A, Lockwood A, Green R. Case management for people with severe mental disorders (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Marshall M, Crowther R, Almaraz-Serrano A, et al. Day hospital versus admission for acute psychiatric disorders (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Marshall M, Crowther R, Almaraz-Serrano A M, Tyrer P. Day hospital versus out-patient care for psychiatric disorders (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Mojtabai R, Nicholson R A, Carpenter B N. Role of psychosocial treatments in management of schizophrenia: A meta-analytic review of controlled outcome studies. Schizophrenia Bulletin 1998; 24: 569–587
   PubMed Web of Science ®Google Scholar
• Mueser K T, Bond G R, Drake R E, Resnick S G. Models of community care for severe mental illness: A review of research on case management. Schizophrenia Bulletin 1998; 24: 37–74
   PubMed Web of Science ®Google Scholar
• Neto J IS, Lima M S, Soares B GO. Amisulpride for schizophrenia (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Nicol M M, Robertson L, Connaughton J A. Life skills programmes for chronic mental illnesses (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Peuskens J, De Hert M, Jones M. The clinical value of risperidone and olanzapine: A meta-analysis of efficacy and safety. International Journal of Psychiatry in Clinical Practice 2001; 5: 179–187
   PubMed Web of Science ®Google Scholar
• Pharoah F M, Mari J J, Streiner D. Family intervention for schizophrenia (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Rector N A, Beck A T. Cognitive behavioral therapy for schizophrenia: An empirical review. Journal of Nervous and Mental Disease 2001; 189: 278–287
   PubMed Web of Science ®Google Scholar
• Sailas E, Fenton M. Seclusion and restraint for people with serious mental illnesses (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Srisurapanont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Tharyan P, Adams C E. Electroconvulsive therapy for schizophrenia (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Tuunainen A, Wahlbeck K, Gilbody S M. Newer atypical antipsychotic medication versus clozapine for schizophrenia (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Tyrer P, Coid J, Simmonds S, Joseph P, Marriott S. Community mental health teams (CMHTs) for people with severe mental illnesses and disordered personality (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Wahlbeck K, Cheine M, Essali M A. Clozapine versus typical neuroleptic medication for schizophrenia (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• Waraich P S, Adams C E, Roque M, Hamill K M, Marti J. Haloperidol dose for the acute phase of schizophrenia (Cochrane Review). The Cochrane Library. Issue 1. Update Software, Oxford 2003
   Google Scholar
• National Collaborating Centre for Mental Health. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. Clinical Guideline 1. National Institute for Clinical Excellence. Abba Litho Sales Ltd., London 2002; 62, ISBN: 1–84257–257–1
   Google Scholar
• National Collaborating Centre for Mental Health. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. Clinical practice algorithms and pathways to care. National Institute for Clinical Excellence. Abba Litho Sales Ltd., London 2002; 3, ISBN: 1–84257–257–1
   Google Scholar
• National Collaborating Centre for Mental Health. Treating and managing schizophrenia (core interventions). Understanding NICE guidance - information for people with schizophrenia, their advocates and carers, and the public. National Institute for Clinical Excellence. Abba Litho Sales Ltd., London 2002; 39, ISBN: 1–84257–258-X
   Google Scholar
• Bassett A, Addington D. Canadian clinical practice guidelines for the treatment of schizophrenia. Canadian Journal of Psychiatry 1998; 43, Suppl. 2
   Web of Science ®Google Scholar
• APA. Practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry 1997; 154: 1–63, (Suppl 4)
   Web of Science ®Google Scholar
• Guideline Development Group. Psychosocial Interventions for the Management of Schizophrenia. A National Clinical Guideline. Edinburgh 1998, Scottish Intercollegiate Guidelines Network (SIGN) Pub. no. 30
   Google Scholar
• The Schizophrenias: guidelines for an holistic approach to clinical practice. New South Wales Health Department, NSW 2001, ISBN: 07347–33241–4
   Google Scholar
• The Expert Consensus Panel. Treatment of schizophrenia: the expert consensus guideline series. Journal of Clinical Psychiatry 1999; 60: 3–80, (Suppl 11)
   Web of Science ®Google Scholar
• Evidence Base for the Clinical Standards for Schizophrenia. Clinical Standards Board for Scotland, Edinburgh 2001, ISBN: 1–903766–02–8
   Google Scholar
• New South Wales Health Department. The Management of People with Co-Existing Mental Health and Substance Use Disorder: Service Delivery Guidelines. NSW 2000, State Health Publication No. (CMH) 000040. ISBN: 0 7347–3154-X
   Google Scholar
• Centre for Mental Health. Mental Health for Emergency Deprtments - A reference guide (pocket version). New South Wales Health Department, NSW 2001, SHPN: (CMH) 010032. ISBN: 0 7347–3273–2
   Google Scholar
• Best Practices - Concurrent Mental Health and Substance Use Disorders. Health Canada. 2002; 161, Cat. H39–599/2001–2E, ISBN 0–662–31388–7
   Google Scholar
• Strasser K M. Smoking Reduction and Cessation for People with Schizophrenia- Guidelines for General Practitioners. 2001, These guidelines are the result of a collaborative enterprise between SANE Australia and the University of Melbourne Department of Psychiatry, funded by the Victorian Department of Human Services Victorian and Quit Victoria. Endorsed by the Royal Australian College of General Practitioners and the Royal Australian and New Zealand College of Psychiatrists
   Google Scholar